youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
NVAX:NASDAQ
Novavax Inc
$9.53
arrow_downward
-5.46%(-0.55) 1D
$9.71
arrow_upward
+1.92% (+0.18)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$10.10
High
$10.38
Low
$9.48
Mkt. cap
1.57B
Avg. vol.
7.69M
Volume
4.09M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
Open
$10.10
High
$10.38
Low
$9.48
Mkt. cap
1.57B
Avg. vol.
7.69M
Volume
4.09M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
investingLive
·
50 minutes ago
Nasdaq’s worst month since March 2025 puts returns on AI spending in focus, says BlackRock
KuCoin
·
7 minutes ago
Nasdaq-100 Enters Third Correction This Year Amid AI Concerns
Yahoo Finance
·
6 hours ago
Update: Dow Rises in Choppy Session Amid US Election Anxiety
Investor's Business Daily
·
2 hours ago
Dow Jones Futures: AI Trade Dives As Apple Tumbles On Earnings; Midterm Elections Next
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com
Analyst ratings
Based on 4 analysts giving stock ratings to NVAX in the past 3 months
Hold
Buy
1
Hold
1
Sell
2
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for NVAX in the last 3 months.
Highest
Current $9.53
$18.00 (+88.88%)
Average
$10.75 (+12.80%)
Lowest
$8.00 (-16.05%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Pete Stavropoulos Cantor Fitzgerald | Buy | Reiterated | $18.00 | +88.9% | 10/26/2026 |
Alec Stranahan Bank of America Securities | Sell | Maintained | $8.00 | -16.1% | 10/23/2026 |
Geoff Meacham Citi | Sell | Maintained | $8.00 | -16.1% | 10/16/2026 |
Unknown Analyst Cantor Fitzgerald | Buy | Maintained | $18.00 | +88.9% | 08/06/2026 |
Chris LoBianco TD Cowen | Hold | Reiterated | $9.00 | -5.6% | 08/04/2026 |
Thomas Shrader BTIG | Buy | Maintained | $19.00 | +99.4% | 06/11/2026 |
Steve Scala TD Cowen | Hold | Reiterated | $9.00 | -5.6% | 05/06/2026 |
Sean Lee CFA H.C. Wainwright | Buy | Reiterated | $16.00 | +67.9% | 04/21/2026 |
Mayank Mamtani B. Riley Securities | Buy | Maintained | $18.00 | +88.9% | 04/09/2026 |
Next call in 2 days
Thu, Nov 5, 8:30 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.42
Revenue / Est. (USD)
- / 50.42M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 70.44M | 147.14M | 139.51M | 56.70M |
Cost of goods sold | 103.70M | 135.96M | 112.43M | 72.29M |
Cost of revenue | 103.70M | 135.96M | 112.43M | 72.29M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 46.12M | -9.76M | 37.12M | 35.21M |
Operating expense | 46.12M | -9.76M | 37.12M | 35.21M |
Total operating expenses | 149.82M | 126.20M | 149.54M | 107.50M |
Operating income | -79.38M | 20.94M | -10.03M | -50.81M |
Other non operating income | 178.00K | 53.37M | 525.00K | 119.00K |
EBT including unusual items | -203.04M | 17.90M | -8.51M | -51.68M |
EBT excluding unusual items | -75.68M | 29.41M | -3.11M | -47.58M |
Income tax expense | -657.00K | 376.00K | 985.00K | 1.71M |
Effective tax rate | 0.32% | 2.10% | -11.58% | -3.31% |
Other operating expenses | - | - | - | - |
Net income | -202.38M | 17.53M | -9.49M | -53.39M |
Net profit margin | -287.29% | 11.91% | -6.80% | -94.16% |
Earnings per share | -0.47 | 0.11 | -0.06 | -0.32 |
Interest and investment income | 7.20M | - | 7.10M | 6.90M |
Interest expense | -5.48M | -27.99M | -4.90M | -5.69M |
Net interest expenses | 1.72M | -27.99M | 2.20M | 1.21M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -72.80M | 26.06M | -6.97M | -47.75M |
Gain or loss from assets sale | 97.04M | 807.00K | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events